在许多一期肿瘤免疫治疗试验中，没有观察到剂量限制毒性，也无法确定最大耐受剂量。在这些情况下，剂量寻找可以通过反应生物标志物指导，而不是剂量限制毒性的发生。建议的二期剂量可以定义为具有连续反应生物标志物预定值的均值反应的剂量。为了定位连续生物标志物的平均值，我们借鉴了连续更新方法和准伯努利似然的思想。我们将设计扩展到一个包含多种免疫治疗方案的试验中，以解决寻找建议的二期剂量组合的问题。 © 2023 John Wiley＆Sons Ltd。

In many phase 1 oncology trials of immunotherapies, no dose-limiting toxicities are observed and the maximum tolerated dose cannot be identified. In these settings, dose-finding can be guided by a biomarker of response rather than the occurrences of dose-limiting toxicity. The recommended phase 2 dose can be defined as the dose with mean response equal to a prespecified value of a continuous response biomarker. To target the mean of a continuous biomarker, we build on the idea of the continual reassessment method and the quasi-Bernoulli likelihood. We extend the design to a problem of finding the recommended phase 2 dose combination in a trial with multiple immunotherapies.© 2023 John Wiley & Sons Ltd.